Skip to main content

BIMI Announces Results of 2023 Special meeting of Shareholders.

Written by Customer Service on . Posted in Public Companies.

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — BIMI International Medical Inc. (NASDAQ: BIMI) (“BIMI” or the “Company”), a healthcare products and services provider, today announced the results of the Company’s 2023 Special Meeting of Shareholders held on April 13, 2023 at the offices of the Company, 15th Floor, 725 5th Avenue, New York, NY, 10022.

At the Special Meeting, the shareholders voted and approved,

 1.In accordance with Nasdaq Marketplace Rule 5635(a), the issuance of shares of the Company’s common stock pursuant to the stock purchase agreement dated as of July 5, 2022, as amended on February 27, 2023, between the Company and Mr. Fnu Oudom the Chairman of the board of directors, whereby the Company agreed to issue 270,000 shares of common stock to Mr. Oudom as partial consideration for the Company’s purchase of 100% of the equity interests in Phenix Bio Inc. from Mr. Oudom and 5,000,000 shares of common stock to Mr. Oudom in the event Phenix attains a profit of $2,500,000 in 2023.
   
 2.In accordance with Nasdaq Marketplace Rule 5635(d), the issuance of 2,000,000 shares of common stock to Mr. Oudom in consideration for his payment of $3,000,000 pursuant to a stock purchase agreement dated as of February 27, 2023, between the Company and Mr. Oudom.
   
 3.In accordance with Nasdaq Marketplace Rule 5635(d), the issuance of 1,330,000 shares of common stock to Mr. Oudom pursuant to an agreement dated as of February 27, 2023, in consideration for the prepayment of a $2,000,000 convertible promissory note sold by the Company to Mr. Oudom on December 6, 2022.

Upon the approval of the issuance of all these shares, and if Phenix attains profits of $2.5 million in 2023, an additional 8,600,000 shares of common Stock will be issued to Mr. Oudom; as a result, Mr. Oudom will hold approximately 79.34 % of the Company’s common stock outstanding post issuance (or 65.40 % before Phenix achieves the $2.5 million profitability milestone).

Mr. Tiewei Song, the CEO of BIMI International Medical Inc., said, “On behalf of everyone at BIMI International Medical Inc., I would like to express our gratitude to Chairman Fnu Oudom for his unwavering support of our company and its subsidiaries.”

About BIMI International Medical Inc.
BIMI International Medical Inc. is a healthcare products and services provider, offering a broad range of healthcare products and related services. For more information, please visit www.usbimi.com.

Safe Harbor Statement
Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, the Company’s ability to achieve profitable operations, its ability to continue to operate as a going concern, its ability to continue to meet NASDAQ continued listing requirements, the effects of the spread of COVID-19, the demand for the Company’s products and services in the People’s Republic of China, general economic conditions and other risk factors detailed in the Company’s annual report and other filings with the United States Securities and Exchange Commission.

Investor Relations Contact
Investor Relations Department of BIMI International Medical Inc.
Email: vinson@usbimi.com
Tel: +1 949 981 6274 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.